{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:22:27Z","timestamp":1789788147280,"version":"4.0.1"},"reference-count":71,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Brain metastasis is a poor prognostic factor in patients with cancer. Despite showing efficacy in many extracranial tumors, immunotherapy with anti\u2013PD-1 mAb or anti\u2013CTLA4 mAb seems to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti\u2013PD-1 and anti\u2013CTLA4 mAbs has a potent antitumor effect on brain metastasis, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies. In this study, we analyzed the tumor-infiltrating lymphocytes in murine models of brain metastasis that responded to anti\u2013CTLA4 and anti\u2013PD-1 mAbs. Activated CD4+ T follicular helper (TFH) cells with high CTLA4 expression characteristically infiltrated the intracranial TME, which were activated by combination anti\u2013CTLA4 and anti\u2013PD-1 treatment. The loss of TFH cells suppressed the additive effect of CTLA4 blockade on anti\u2013PD-1 mAb. B-cell\u2013activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) produced by abundant myeloid cells, particularly CD80hiCD206lo proinflammatory M1-like macrophages, in the intracranial TME induced B-cell and TFH-cell infiltration and activation. Furthermore, the intracranial TME of patients with non\u2013small cell lung cancer featured TFH- and B-cell infiltration as tertiary lymphoid structures. Together, these findings provide insights into the immune cell cross-talk in the intracranial TME that facilitates an additive antitumor effect of CTLA4 blockade with anti\u2013PD-1 treatment, supporting the potential of a combination immunotherapeutic strategy for brain metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>B-cell and CD4+ T follicular helper cell activation via BAFF\/APRIL from abundant myeloid cells in the intracranial tumor microenvironment enables a combinatorial effect of CTLA4 and PD-1 blockade in brain metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-24-2274","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:12:18Z","timestamp":1736777538000},"page":"1082-1096","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy"],"prefix":"10.1158","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0882-8154","authenticated-orcid":false,"given":"Toshifumi","family":"Ninomiya","sequence":"first","affiliation":[{"name":"1Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."},{"name":"2Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9286-1803","authenticated-orcid":false,"given":"Naoya","family":"Kemmotsu","sequence":"additional","affiliation":[{"name":"1Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."},{"name":"3Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8866-0684","authenticated-orcid":false,"given":"Fumiaki","family":"Mukohara","sequence":"additional","affiliation":[{"name":"1Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."},{"name":"4Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-0160","authenticated-orcid":false,"given":"Masaki","family":"Magari","sequence":"additional","affiliation":[{"name":"5Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7079-3984","authenticated-orcid":false,"given":"Ai","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"6Medical Protein Engineering, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2627-8524","authenticated-orcid":false,"given":"Youki","family":"Ueda","sequence":"additional","affiliation":[{"name":"1Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-0677","authenticated-orcid":false,"given":"Takamasa","family":"Ishino","sequence":"additional","affiliation":[{"name":"1Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-5469","authenticated-orcid":false,"given":"Joji","family":"Nagasaki","sequence":"additional","affiliation":[{"name":"1Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-9180","authenticated-orcid":false,"given":"Tomohiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"7Department of Orthopaedic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9148-6445","authenticated-orcid":false,"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"8Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5587","authenticated-orcid":false,"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3896-5732","authenticated-orcid":false,"given":"Kota","family":"Tachibana","sequence":"additional","affiliation":[{"name":"10Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1233-2793","authenticated-orcid":false,"given":"Joji","family":"Ishida","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-5125","authenticated-orcid":false,"given":"Yoshihiro","family":"Otani","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9484-2980","authenticated-orcid":false,"given":"Shota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7588-6745","authenticated-orcid":false,"given":"Shinichi","family":"Toyooka","sequence":"additional","affiliation":[{"name":"4Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Science, Okayama University, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-6096","authenticated-orcid":false,"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[{"name":"2Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9910-0164","authenticated-orcid":false,"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[{"name":"1Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan."},{"name":"11Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan."},{"name":"12Kindai University Faculty of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"2026042320321310300_bib1","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-07-0096","article-title":"CNS metastasis: an old problem in a new guise","volume":"13","author":"Aragon-Ching","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026042320321310300_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1470-2045(02)00819-7","article-title":"Metastasis to and from the central nervous system\u2013the \u2018relatively protected site","volume":"3","author":"Subramanian","year":"2002","journal-title":"Lancet Oncol"},{"key":"2026042320321310300_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","article-title":"The evolving landscape of brain metastasis","volume":"4","author":"Valiente","year":"2018","journal-title":"Trends Cancer"},{"key":"2026042320321310300_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026042320321310300_bib5","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol"},{"key":"2026042320321310300_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2026042320321310300_bib7","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2026042320321310300_bib8","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2026042320321310300_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2026042320321310300_bib10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026042320321310300_bib11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4161\/onci.20687","article-title":"Ipilimumab in a phase II trial of melanoma patients with brain metastases","volume":"1","author":"Margolin","year":"2012","journal-title":"Oncoimmunology"},{"key":"2026042320321310300_bib12","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026042320321310300_bib13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"2026042320321310300_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026042320321310300_bib15","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026042320321310300_bib16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026042320321310300_bib17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 part 1","volume":"18","author":"Reck","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026042320321310300_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026042320321310300_bib19","doi-asserted-by":"crossref","first-page":"115052","DOI":"10.1016\/j.ejca.2024.115052","article-title":"Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: a multicenter single-arm phase 2 trial (NIke, LOGiK 2004)","volume":"212","author":"Tsuchiya-Kawano","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026042320321310300_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"2026042320321310300_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"2026042320321310300_bib22","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"key":"2026042320321310300_bib23","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"2026042320321310300_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1172\/JCI36666","article-title":"Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages","volume":"120","author":"Wilson","year":"2010","journal-title":"J Clin Invest"},{"key":"2026042320321310300_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1601-0825.2011.01885.x","article-title":"TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice","volume":"18","author":"Vosters","year":"2012","journal-title":"Oral Dis"},{"key":"2026042320321310300_bib26","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1002\/1873-3468.14468","article-title":"The immunoreceptor SLAMF8 promotes the differentiation of follicular dendritic cell-dependent monocytic cells with B cell-activating ability","volume":"596","author":"Magari","year":"2022","journal-title":"FEBS Lett"},{"key":"2026042320321310300_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12033-014-9738-0","article-title":"Dramatic increase in expression of a transgene by insertion of promoters downstream of the cargo gene","volume":"56","author":"Sakaguchi","year":"2014","journal-title":"Mol Biotechnol"},{"key":"2026042320321310300_bib28","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3892\/or.2015.3885","article-title":"The cysteine-rich core domain of REIC\/Dkk-3 is critical for its effect on monocyte differentiation and tumor regression","volume":"33","author":"Kinoshita","year":"2015","journal-title":"Oncol Rep"},{"key":"2026042320321310300_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","article-title":"Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement","volume":"4","author":"Linsley","year":"1996","journal-title":"Immunity"},{"key":"2026042320321310300_bib30","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1158\/0008-5472.CAN-22-1744","article-title":"Stress-mediated attenuation of translation undermines T-cell activity in cancer","volume":"82","author":"Riesenberg","year":"2022","journal-title":"Cancer Res"},{"key":"2026042320321310300_bib31","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026042320321310300_bib32","doi-asserted-by":"crossref","first-page":"e007239","DOI":"10.1136\/jitc-2023-007239","article-title":"Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models","volume":"11","author":"Phadke","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026042320321310300_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"2026042320321310300_bib34","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026042320321310300_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"2026042320321310300_bib36","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026042320321310300_bib37","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"2026042320321310300_bib38","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/ncomms15067","article-title":"T follicular helper and T follicular regulatory cells have different TCR specificity","volume":"8","author":"Maceiras","year":"2017","journal-title":"Nat Commun"},{"key":"2026042320321310300_bib39","doi-asserted-by":"crossref","first-page":"e001187","DOI":"10.1136\/jitc-2020-001187","article-title":"A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy","volume":"8","author":"S\u00e1nchez-Alonso","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026042320321310300_bib40","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1084\/jem.192.11.1545","article-title":"Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production","volume":"192","author":"Breitfeld","year":"2000","journal-title":"J Exp Med"},{"key":"2026042320321310300_bib41","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"2026042320321310300_bib42","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","article-title":"The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma","volume":"4","author":"Nagasaki","year":"2020","journal-title":"Blood Adv"},{"key":"2026042320321310300_bib43","doi-asserted-by":"crossref","first-page":"113797","DOI":"10.1016\/j.celrep.2024.113797","article-title":"Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment","volume":"43","author":"Zhou","year":"2024","journal-title":"Cell Rep"},{"key":"2026042320321310300_bib44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41423-023-01027-8","article-title":"CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4+ T cells","volume":"20","author":"Hao","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"2026042320321310300_bib45","doi-asserted-by":"crossref","first-page":"e002157","DOI":"10.1136\/jitc-2020-002157","article-title":"Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1\/PD-1 efficacy","volume":"9","author":"Niogret","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026042320321310300_bib46","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"2026042320321310300_bib47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.immuni.2022.01.018","article-title":"Tfh-cell-derived interleukin 21 sustains effector CD8+ T cell responses during chronic viral infection","volume":"55","author":"Zander","year":"2022","journal-title":"Immunity"},{"key":"2026042320321310300_bib48","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.4049\/jimmunol.1300378","article-title":"Insights into the role of Bcl6 in follicular Th cells using a new conditional mutant mouse model","volume":"191","author":"Hollister","year":"2013","journal-title":"J Immunol"},{"key":"2026042320321310300_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri2217","article-title":"Germinal centres: role in B-cell physiology and malignancy","volume":"8","author":"Klein","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2026042320321310300_bib50","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1038\/onc.2017.261","article-title":"Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas","volume":"36","author":"Yan","year":"2017","journal-title":"Oncogene"},{"key":"2026042320321310300_bib51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"2026042320321310300_bib52","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1182\/blood-2002-10-3123","article-title":"Macrophage- and dendritic cell\u2013dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF","volume":"101","author":"Craxton","year":"2003","journal-title":"Blood"},{"key":"2026042320321310300_bib53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","article-title":"Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr Biol"},{"key":"2026042320321310300_bib54","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2026042320321310300_bib55","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"2026042320321310300_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"2026042320321310300_bib57","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026042320321310300_bib58","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026042320321310300_bib59","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042320321310300_bib60","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026042320321310300_bib61","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.annonc.2023.08.012","article-title":"High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab","volume":"34","author":"Shiraishi","year":"2023","journal-title":"Ann Oncol"},{"key":"2026042320321310300_bib62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function","volume":"24","author":"Teft","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"2026042320321310300_bib63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat Neurosci"},{"key":"2026042320321310300_bib64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1215\/15228517-2006-008","article-title":"The role of human glioma-infiltrating microglia\/macrophages in mediating antitumor immune responses","volume":"8","author":"Hussain","year":"2006","journal-title":"Neuro Oncol"},{"key":"2026042320321310300_bib65","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.it.2023.10.007","article-title":"Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies","volume":"44","author":"Nasir","year":"2023","journal-title":"Trends Immunol"},{"key":"2026042320321310300_bib66","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.neuron.2014.07.027","article-title":"TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord","volume":"83","author":"Kroner","year":"2014","journal-title":"Neuron"},{"key":"2026042320321310300_bib67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/imr.12405","article-title":"Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers","volume":"271","author":"Dieu-Nosjean","year":"2016","journal-title":"Immunol Rev"},{"key":"2026042320321310300_bib68","doi-asserted-by":"crossref","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"2026042320321310300_bib69","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"2026042320321310300_bib70","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/0008-5472.CAN-23-0620","article-title":"The evolving landscape of B cells in cancer metastasis","volume":"83","author":"Ramos","year":"2023","journal-title":"Cancer Res"},{"key":"2026042320321310300_bib71","doi-asserted-by":"crossref","first-page":"109422","DOI":"10.1016\/j.celrep.2021.109422","article-title":"Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts","volume":"36","author":"Rodriguez","year":"2021","journal-title":"Cell Rep"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-24-2274\/3533010\/can-24-2274.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/6\/1082\/3552080\/can-24-2274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/6\/1082\/3552080\/can-24-2274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:32:26Z","timestamp":1776990746000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/85\/6\/1082\/752762\/Myeloid-Cells-Induce-Infiltration-and-Activation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":71,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,13]]},"published-print":{"date-parts":[[2025,3,14]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-24-2274","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.28595192","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595186","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595198","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595195","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595201","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595222","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595210","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595189","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595216","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595204","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595225","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595219","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.28595207","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.7719710","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}